Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(10); doi: 10.25236/FMSR.2023.051018.

Clinical application analysis of phosphomycin aminotriol granules in urinary system infections


Li Li, Xianpeng Shi, Tongfei Yang, Yaning Zhu, Hang Feng, Zhuo Li, Peng Zhang

Corresponding Author:
Zhuo Li

Pharmacy Department, Shaanxi Provincial People's Hospital, Xi'an, China


Urinary tract infections are prevalent infectious diseases in clinical settings. The increasing irrational use of antimicrobial drugs has contributed to a gradual rise in the resistance of pathogens causing UTIs. The introduction of new phosphomycin oral formulations, characterized by high concentrations and prolonged duration in body fluids, minimal side effects, and relatively low resistance of relevant infecting strains, has made them a common choice for UTI treatment. However, improper use may still lead to bacterial resistance issues. This study extracts and analyzes data from UTI patients treated in our hospital during three months in 2022, focusing on the medication patterns in antimicrobial therapy. Specific issues related to the inappropriate and non-standard use of phosphomycin aminotriol granules are identified, including instances of non-indicated use, prolonged treatment duration for uncomplicated lower urinary tract infections beyond guideline recommendations, and the importance of administering the medication before meals or after gastric emptying. These issues are delineated to facilitate targeted clinical improvements.


Phosphomycin amdinotriol granules; Urinary tract infection; Clinical application analysis

Cite This Paper

Li Li, Xianpeng Shi, Tongfei Yang, Yaning Zhu, Hang Feng, Zhuo Li, Peng Zhang. Clinical application analysis of phosphomycin aminotriol granules in urinary system infections. Frontiers in Medical Science Research (2023) Vol. 5, Issue 10: 125-129. https://doi.org/10.25236/FMSR.2023.051018.


[1] Liu Y. N., Tang J. H., Liu J. L., Zhang W., Li X. F. (2021) Sensitivity Analysis of Fosfomycin to Common Pathogenic Bacteria in Urinary Tract Infections. Pharmacy and Clinical Research, 29, 35-38. 

[2] Michalopoulos A. S., Livaditis I. G., Gougoutas V. (2011) The Revival of Fosfomycin. International Journal of Infectious Diseases, 15, 732-739. 

[3] Albini E., Belluco G., Marca G. (1986) Influence of pH, Inoculum, and Media on the In Vitro Bactericidal Activity of Fosfomycin Trometamol, Norfloxacin, and Cotrimoxazole. Chemioterapia, 5, 268-272. 

[4] Zhang Y., Lu X. Z., Qi W. M., Wang L., Xu Y. X., Liu C. X. (2023) Clinical Efficacy and Value of Fosfomycin Aminotriol in the Treatment of Lower Urinary Tract Infection. Marriage, Maternity & Health, 29, 76-78. 

[5] Kahan F. M., Kahan J. S., Cassidy P. J. (1974) The Mechanism of Action of Fosfomycin (Phosphonomycin). Annals of the New York Academy of Sciences, 235, 364-386. 

[6] Sastry S., Doi Y. (2016) Fosfomycin: Resurgence of an Old Companion. Journal of Infection and Chemotherapy, 22, 273-280. 

[7] Ternes B., Wagenlehner F. M. E. (2020) Leitliniengerechte Therapie von Harnwegsinfektionen [Guideline-based treatment of urinary tract infections]. Urologe A, 59, 550-558. 

[8] Bixler B. R., Anger J. T. (1922) Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline. J Urol, 208, 754-756. 

[9] de Cueto M., Aliaga L., Alós J. I., Canut A., Los-Arcos I., Martínez J. A., Mensa J., Pintado V., Rodriguez-Pardo D., Yuste J. R., Pigrau C. (2017) Executive summary of the diagnosis and treatment of urinary tract infection: Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin, 35, 314-320. 

[10] Jin N. S., He J. Y., Feng W., Zhang X. (2022) Research Progress of Fosfomycin in the Treatment of Multidrug-Resistant Enterobacteriaceae Infections. Practical Pharmacy and Clinical Remedies, 25, 568-572.